Protection against N. gonorrhoeae induced by OMV-based Meningococcal Vaccines are associated with cross-species directed humoral and cellular immune responses
Weiyan ZhuiD, Andreea WaltmanniD, Marguerite B. LittleiD, Kristie L. ConnollyiD, Kathryn MatthiasiD, Keena S. ThomasiD, Mary C. GrayiD, Aleksandra E. SikoraiD, Alison K. CrissiD, Margaret C. BashiD, Andrew N. MacintyreiD, Ann E. JerseiD, Joseph A. DuncaniD
Abstract
Limited protective immunologic responses to natural N. gonorrhoeae infection and a lack of knowledge about mechanisms of protection have hampered development of an effective vaccine. Recent studies in humans and mice have found meningococcal outer membrane vesicle-containing vaccines (OMV) induce cross species immune responses against gonococci and are associated with protection. The exact mechanisms or how humoral and cellular immunity are related to protection, remain unclear. To study this, we immunized mice with two meningococcal OMV-containing vaccines known to accelerate clearance of N. gonorrhoeae, 4CMenB and OMV from an engineered N. meningitidis strain lacking major surface antigens PorA, PorB, and Rmp (MC58 {Delta}ABR). We assessed serologic and cellular immune signatures associated with these immunizations and assessed bacterial clearance in the mice using a vaginal/cervical gonococcal infection model. Mice immunized with 4CMenB or MC58 {Delta}ABR demonstrated shortened courses of recovery of vaginal N. gonorrhoeae compared to control mice immunized with alum alone. Vaccination with 4CMenB or MC58{Delta}ABR OMV elicited serum and vaginal cross-reactive anti-Ng-OMV antibody responses that were augmented after vaginal challenge with N. gonorrhoeae. Further, splenocytes in 4CMenB and MC58 {Delta}ABR immunized mice exhibited elevated cytokine production after restimulation with heterologous N. gonorrhoeae OMV when compared to splenocytes from Alum immunized mice. We further tested for correlations between bacterial burden and the measured anti-gonococcal immune responses within each vaccination group and found different immunologic parameters associated with reduced bacterial burden for each vaccine. Our findings suggest the cross-protection against gonococcal infection induced by different meningococcal OMV vaccines is likely multifactorial and mediated by different humoral and cellular immune responses induced by these two vaccines.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 12
- FWCI
- 5.93
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
I. Leduc, K. L. Connolly, … A. Jerse·PLOS PathogensPeer-reviewed·Dec 8, 2020
- Preclinical characterization of immune responses induced by a candidate gonococcal native Outer Membrane Vesicle vaccine
Ilaria Onofrio, Sthefany Pagliari, … Calman Alexander MacLennan·mSpherePeer-reviewed·Jun 22, 2026
- Meningococcal vaccine Bexsero elicits a robust cellular immune response that targets but is not consistently protective against Neisseria gonorrhoeae during murine vaginal infection
Joseph John Zeppa, Jamie E. Fegan, … Scott D. Gray‐Owen·mSpherePeer-reviewed·Apr 16, 2025
- Evaluating vaccine-elicited antibody activities against Neisseria gonorrhoeae: cross-protective responses elicited by the 4CMenB meningococcal vaccine
M. C. Gray, K. S. Thomas, … A. K. Criss·bioRxiv·Aug 3, 2023
- Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria
Epshita A. Islam, Jamie E. Fegan, … Scott D. Gray‐Owen·VaccinePeer-reviewed·Sep 12, 2024
- Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens
M. Troisi, M. Fabbrini, … An·bioRxiv·Dec 7, 2023